Cargando…

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells

Hepatocellular carcinoma is one of the most common cancer types worldwide. In cases of advanced-stage disease, sorafenib is considered the treatment of choice. However, resistance to sorafenib remains a major obstacle for effective clinical application. Based on integrated phosphoproteomic and The C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Li-Zhu, Chen, Chih-Ta, Li, Nien-Chen, Lin, Liang-Chun, Huang, Bo-Shih, Chang, Ya-Hui, Chow, Lu-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795419/ https://www.ncbi.nlm.nih.gov/pubmed/33379356 http://dx.doi.org/10.3390/ijms22010224

Ejemplares similares

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

TATA-box-binding protein promotes hepatocellular carcinoma metastasis through epithelial-mesenchymal transition
por: Cao, Jiayi, et al.
Publicado: (2023)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation
por: Dong, Shuying, et al.
Publicado: (2015)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
por: Hu, Bo, et al.
Publicado: (2019)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
por: Xu, Gui-Li, et al.
Publicado: (2020)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells
por: Chen, Yu-Ching, et al.
Publicado: (2016)

KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification
por: Kuang, Ye, et al.
Publicado: (2022)

Sorafenib Inhibits Epithelial-Mesenchymal Transition through an Epigenetic-Based Mechanism in Human Lung Epithelial Cells
por: Zhang, Juyong, et al.
Publicado: (2013)

Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF-β-Induced Epithelial-Mesenchymal Transition
por: Jia, Lining, et al.
Publicado: (2015)

Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition
por: Fouquet, Grégory, et al.
Publicado: (2022)

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Wang, Shanshan, et al.
Publicado: (2023)

Reversal of TGF-β-induced epithelial–mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor
por: Modi, Siddharth J., et al.
Publicado: (2021)

LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells: LIMT contributes to sorafenib chemoresistance in HCC
por: Sun, Jing, et al.
Publicado: (2021)

HMGA2 induces epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells
por: LUO, YIZHOU, et al.
Publicado: (2013)

Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells
por: Chen, Chih-Ta, et al.
Publicado: (2020)

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma
por: Liu, Ting, et al.
Publicado: (2021)

Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation
por: Chen, Y-L, et al.
Publicado: (2013)

Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells
por: Chen, Shuo, et al.
Publicado: (2018)

Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells
por: Chen, Shuo, et al.
Publicado: (2022)

Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells
por: Dong, Jiejie, et al.
Publicado: (2017)

Up-regulation of RNF187 induces hepatocellular carcinoma cell epithelial to mesenchymal transitions
por: Yu, Song-Lin, et al.
Publicado: (2017)

PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial-mesenchymal transition
por: Liu, Hongyu, et al.
Publicado: (2019)

Goosecoid Promotes the Metastasis of Hepatocellular Carcinoma by Modulating the Epithelial-Mesenchymal Transition
por: Xue, Tong-Chun, et al.
Publicado: (2014)

Role of IQGAP3 in metastasis and epithelial–mesenchymal transition in human hepatocellular carcinoma
por: Shi, Yongjie, et al.
Publicado: (2017)

Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition
por: Tian, Chuntao, et al.
Publicado: (2022)

Role of LncRNAs in the Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Ge, Xiaoyong, et al.
Publicado: (2021)

MiR-195 suppresses the metastasis and epithelial–mesenchymal transition of hepatocellular carcinoma by inhibiting YAP
por: Yu, Shuo, et al.
Publicado: (2017)

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Hirao, Akihiro, et al.
Publicado: (2021)

Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma
por: Song, Jaewhan
Publicado: (2020)

Epithelial Mesenchymal and Endothelial Mesenchymal Transitions in Hepatocellular Carcinoma: A Review
por: Gurzu, Simona, et al.
Publicado: (2019)

HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition
por: Huan, Hong-bo, et al.
Publicado: (2017)

ECM1 promotes migration and invasion of hepatocellular carcinoma by inducing epithelial-mesenchymal transition
por: Chen, Hao, et al.
Publicado: (2016)

High expression of spliced X-Box Binding Protein 1 in lung tumors is associated with cancer aggressiveness and epithelial-to-mesenchymal transition
por: Tavernier, Quentin, et al.
Publicado: (2020)

FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition
por: Zhang, Xiang, et al.
Publicado: (2019)

Fatty acid‐binding protein 5 function in hepatocellular carcinoma through induction of epithelial–mesenchymal transition
por: Ohata, Takanori, et al.
Publicado: (2017)

The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma
por: Cheng, Chiung-Chi, et al.
Publicado: (2019)

RNA Binding Motif Protein 3 Promotes Cell Metastasis and Epithelial–Mesenchymal Transition Through STAT3 Signaling Pathway in Hepatocellular Carcinoma
por: Zhang, Lu, et al.
Publicado: (2022)

The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways
por: Adenina, Syarinta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g6o86ioqdthuqi7slbck4c6okj